Skip to main content

Table 1 Main characteristics of included studies

From: Prevalence and prognostic value of elevated troponins in patients hospitalised for coronavirus disease 2019: a systematic review and meta-analysis

Study author Location Design Date of admission Patients Comorbidities (HTN/DM/CVD, %) Disease severitya Date of last follow-up Overall mortality, % Mortality of pts with elevated troponin on admission, %
No. (male, %) Age, years
Arcari et al. Rome, Italy Retrospective, multi-centre Mar 15–Apr 30 111 (45.9) 72 (17) 55.9/18.9/31.5 NA May 31 20.7 30.8
Azoulay et al. Paris, France Retrospective, multi-centre Feb 21–Apr 24 376 (76.9) 62 [53–68] 49.5/30.3/NA 100% critical, SOFA score 5 [3, 8] May 15 26.4 NA
Barman et al. Istanbul, Turkey Retrospective, multi-centre Mar 20–Apr 20 607 (55.0) 63 (14) 43.8/31.6/19.1 32.1% critical Apr 20 17.0 42.7
Bhatla et al. Philadelphia, USA Retrospective, single-centre Mar 6–May 19 700 (44.9) 50 (18) 49.6/26.0/1.6 11.3% critical May 24 4.3 NA
Bhatraju et al. Seattle, USA Retrospective, multi-centre Feb 24–Mar 9 24 (62.5) 64 (18) NA/58.3/NA 100% critical Mar 23 50.0 NA
Buckner et al. Seattle, USA Retrospective, multi-centre Mar 2–Mar 26 105 (50.5) 69 (range 23–97) 59.0/33.3/38.1 48.6% critical May 8 33.3 NA
Cipriani et al. Padova, Italy Retrospective, single-centre Feb 26–Mar 31 109 (67.0) 70 [60–81] 62.3/24.8/16.5 28.4% critical Apr 1 18.3 43.9
Du et al. Wuhan, China Prospective, single-centre Dec 25–Feb 7 179 (54.2) 58 (14) 32.4/18.4/16.2 NA Mar 24 11.7 31.7
Ferguson et al. North California, USA Retrospective, multi-centre Mar 13–Apr 11 72 NA 36.1/27.8/NA 29.2% critical May 2 6.9 NA
Franks et al. St. Louis, USA Retrospective, single-centre NA 182 (56.6) 64 (range 19–98) NA NA NA 18.7 36.9
Gottlieb et al. Chicago, USA Retrospective, single-centre Mar 4–Jun 21 1483 (53.4) 56 [44–68] 60.5/42.8/15.4 35.6 % critical Jul 10 10.0 NA
Goyal et al. New York, USA Retrospective, multi-centre Mar 3–Mar 27 393 (60.6) 62 [49, 74] 50.1/25.2/13.7 NA Apr 10 10.2 NA
Harmouch et al. Bethlehem, USA Retrospective, single-centre Mar 1–Apr 15 563 (57.1) 63 50.3/35.2/NA 24.3 % critical NA 14.5 36.1
He et al. Wuhan, China Retrospective, single-centre Feb 8–Mar 16 94 (57.4) 69 (10) 59.6/19.1/12.8 100% critical Mar 16 44.7 NA
Heberto et al. Puebla and Mexico City, Mexico Prospective, multi-centre Mar-Apr 254 (65.7) 54 (13) 35.4/31.5/5.5 NA To death or discharge 35.0 NA
Hu et al. Wuhan, China Retrospective, single-centre Jan 8–Feb 20 323 (51.4) 61 (range 23–91) 32.5/14.6/2.2 45.2% severe, 8.0 critical Mar 10 10.8 NA
Huang et al. Jiangsu, China Retrospective, multi-centre Jan 24–Apr 20 60 (58.3) 57 (range 26–97) 23.3/16.7/5.0 100% critical, APACHE II score 14 (5) Apr 20 0 NA
Karbalai et al. Tehran, Iran Retrospective, single-centre Mar-May 386 (61.1) 59 (16) 36.8/34.5/25.1 20.5 % critical To death or discharge 19.9 NA
Lala et al. New York, USA Retrospective, multi-centre Feb 27–Apr 12 2736 (59.6) 66 38.9/26.3/16.6 CURB-65 score 1.26 (1.10) Apr 12 27.3 NA
Lazzeri et al. Florence, Italy Retrospective, single-centre Mar 1–Mar 31 28 (78.6) 62 (10) 89.3/39.3/28.6 100% critical Mar 31 7.1 NA
Li et al. Guangzhou, China Retrospective, single-centre Jan 24–Feb 25 82 (58.5) 45 (16) 26.8/21.9/NA 29.3% severe or critical Feb 29 1.2 7.7
Li et al. Wuhan, China Retrospective, single-centre Jan 29–Apr 1 2068 (48.6) 63 [51, 70] 34.9/14.1/8.8 32.0 % critical Apr 1 8.8 45.9
Lombardi et al. Italy Retrospective, multi-centre Mar 1–Apr 9 614 (70.8) 67 (13) 50.5/19.8/15.0 SOFA score 2 [1, 3] Apr 23 24.1 37.4
Lorente-Ros et al. Madrid, Spain Retrospective, single-centre Mar 18–Mar 23 707 (62.7) 67 (16) 50.5/20.2/10.6 52.1% critical 1 month after admission 19.8 45.2
Lu et al. Wuhan, China Retrospective, single-centre Dec 30–Mar 18 50 (58.0) 66 [58, 73] 38.0/18.0/18.0 100% critical, APACHE II score 12.0 [9.0, 16.3] To death or discharge 60.0 NA
Ma et al. Chongqing, China Retrospective, single-centre Jan 21–Mar 2 84 (57.1) 48 [43, 63] 14.3/11.9/6.0 76.2% severe or critical Mar 2 0 NA
Majure et al. New York, USA Retrospective, multi-centre Mar 1–Apr 27 6247 (59.9) 66 [56, 77] 59.5/36.0/13.3 30.2% critical Apr 30 22.4 43.5
Mejía-Vilet et al. Mexico City, Mexico Prospective, single-centre Mar 16–May 21 569 (66.3) D, 49 [41, 60]; V, 52 [43, 60] 28.5/27.8/NA 35.0% critical May 24 11.1 NA
Nguyen et al. Chicago, USA Retrospective, single-centre Mar 16–Apr 16 356 (48.0) 61 [50, 73] 69.5/42.1/21.9 44% critical May 25 12.6 21.4
Nie et al. Wuhan, China Retrospective, single-centre Jan 12–Mar 12 311 (61.1) 63 [54, 70] NA 57.9% severe, 9.6% critical Mar 20 35.7 NA
Petrilli et al. New York, USA Retrospective, multi-centre Mar 2–Apr 2 1999 (62.6) 62 [50, 74] 37.1/25.2/9.9 36.1% critical Apr 7 14.6 NA
Price-Haywood et al. Louisiana, USA Retrospective, multi-centre Mar 1–Apr 11 1382 (49.0) 63 (15) NA 34.3% critical May 7 23.6 NA
Qi et al. Chongqing, China Retrospective, multi-centre Jan 19–Feb 16 267 (55.8) 48 [35, 65] 7.5/9.7/4.9 18.7% severe or critical Feb 16 1.5 NA
Qin et al. Hubei, China Retrospective, multi-centre Dec 31–Mar 4 3219 (47.7) 57 [45, 66] 27.8/12.8/6.4 NA 28 days after admission 6.0 37.9
Raad et al. Michigan, USA Retrospective, multi-centre Mar 9–Apr 15 1020 (49.9) 63 [52, 73] 72.7/44.3/12.1 50.2% critical To death or discharge 17.6 32.8
Shah et al. Albany, USA Retrospective, multi-centre Mar 2–Jun 7 309 (42.7) 63 (14) 84.5/46.3/9.1 35.6% critical To death or discharge 21.4 NA
Shah et al. San Francisco, USA Retrospective, single-centre Feb 3–Mar 31 26 (NA) NA NA 42.3% critical Apr 25 3.8 NA
Shen et al. Shanghai, China Retrospective, single-centre Jan 20–Feb 29 325 (51.7) 51 [36, 64] 15.6/7.1/3.4 3.1% severe, 4.9% critical Feb 29 0.9 NA
Stefanini et al. Milan, Italy Retrospective, single-centre Up to Apr 1 397 (67.3) 67 [55, 76] 56.7/24.6/8.4 NA To death or discharge 23.2 45.4
Szekely et al. Tel Aviv, Israel Prospective, single-centre Mar 21–Apr 16 100 (63.0) 66 (17) 57.0/29.0/16.0 29.0% severe, 10.0% critical NA NA NA
Tan et al. Wuhan, China Retrospective, multi-centre Feb 8–Apr 6 115 (49.6) 63 [55, 70] 47.0/25.2/NA 63.5% severe, 36.5% critical Apr 6 19.1 70.0
van den Heuvel et al. Nijmegen, Netherlands Retrospective, single-centre Apr 1–May 12 51 (80.4) 63 [51, 68] 41.1/17.6/9.8 37.2% critical To death or discharge 2.0 NA
Wei et al. Chengdu, China Retrospective, multi-centre Jan 16–Mar 10 101 (53.5) 49 [34, 62] 20.8/13.9/5.0 36.6% severe or critical NA 3.0 18.8
Woo et al. Philadelphia, USA Retrospective, multi-centre Mar 1–Apr 30 415 (55.2) 65 (15) 69.9/35.0/18.1 39.3% critical 14 days after admission 21.2 NA
Xu et al. Guangzhou, China Retrospective, single-centre Jan 22–Apr 6 15 (60.0) 44 (13) 26.7/NA/NA 53.3% severe, 6.7% critical Apr 6 0 NA
Yang et al. Wuhan, China Retrospective, single-centre Feb 13–Mar 14 463 (49.9) 60 [50, 69] 38.7/17.3/7.3 8.2% severe, 14.3% critical Mar 28 5.8 40.0
Yu et al. Wuhan, China Prospective, multi-centre Feb 25–Feb 27 226 (61.5) 64 [57, 70] 42.5/20.8/9.7 100% critical, SOFA score 4 [2, 8] Apr 9 38.5 NA
Zeng et al. Shenzhen, China Retrospective, single-centre Jan 11–Apr 1 416 (47.6) NA 14.4/5.5/3.1 8.4% critical Apr 1 0.7 NA
Zhang et al. Wuhan, China Retrospective, single-centre Feb 1–Mar 15 135 (49.6) 56 [42, 68] 20.7/11.9/3.0 22.2% critical NA 13.3 35.0
Zhao et al. Jingzhou, China Retrospective, single-centre Jan 16–Feb 10 91 (53.8) 46 19.8/3.3/0 33.0% severe or critical Feb 10 2.2 NA
Zhou et al. Wuhan, China Retrospective, multi-centre Dec 29–Jan 31 191 (62.3) 56 [46, 67] 30.4/18.8/7.9 34.6% severe, 27.7% critical Jan 31 28.3 95.8
  1. APACHE Acute Physiology and Chronic Health Evaluation; CVD Cardiovascular disease; CURB-65 Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and older; D Derivation cohort; DM Diabetes mellitus; HTN Hypertension; ICU Intensive care unit; NA Not available; SOFA Sequential Organ Failure Assessment; V Validation cohort
  2. Values were mean (standard deviation), median [interquartile rage] or median (range)
  3. aSeverity of illness was assessed based on covid-19 treatment guidelines (see supplementary Table S7)
Back to article page

Journal of Intensive Care

ISSN: 2052-0492